当前位置：
X-MOL 学术
›
Nat. Rev. Clin. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2018-03-13 , DOI: 10.1038/nrclinonc.2018.40 Peter Sidaway
Nature Reviews Clinical Oncology ( IF 81.1 ) Pub Date : 2018-03-13 , DOI: 10.1038/nrclinonc.2018.40 Peter Sidaway
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers
中文翻译：
靶向治疗：Larotrectinib对TRK融合阳性癌症有效
靶向治疗：Larotrectinib对TRK融合阳性癌症有效
更新日期：2018-03-13
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers, Published online: 13 March 2018; doi:10.1038/nrclinonc.2018.40
Targeted therapy: Larotrectinib effective against TRK-fusion-positive cancers中文翻译：
靶向治疗：Larotrectinib对TRK融合阳性癌症有效
靶向治疗：Larotrectinib对TRK融合阳性癌症有效
靶向治疗：Larotrectinib对TRK融合阳性癌症有效，在线发布：2018年3月13日; doi：10.1038 / nrclinonc.2018.40
靶向治疗：Larotrectinib对TRK融合阳性癌症有效
京公网安备 11010802027423号